Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -340.16% is in line with its 5-year average of -375.67%, near the high end of its 5-year range (-1479.45%–-87.25%).
61.35% above its 12-month average of -880.11%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-05-31): -1041.73%.
OPERATING MARGIN
-340.16%
OPERATING MARGIN AVG TTM
-880.11%
OPERATING MARGIN AVG 3Y
-391.07%
OPERATING MARGIN AVG 5Y
-375.67%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+61.35%
CURRENT VS 3Y AVG
+13.02%
CURRENT VS 5Y AVG
+9.45%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Nurix Therapeutics, Inc.
Market Cap
$2.35B
Operating Margin
-340.16%
TTM Avg
-880.11%
3Y Avg
-391.07%
5Y Avg
-375.67%
Market Cap
$2.34B
Operating Margin
15.25%
TTM Avg
15.68%
3Y Avg
15.36%
5Y Avg
13.51%
Market Cap
$2.36B
Operating Margin
42.26%
TTM Avg
35.06%
3Y Avg
13.24%
5Y Avg
-28.82%
Market Cap
$2.37B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.38B
Operating Margin
-0.74%
TTM Avg
-3.89%
3Y Avg
-12.55%
5Y Avg
-17.88%
Market Cap
$2.30B
Operating Margin
-32.45%
TTM Avg
-449.54%
3Y Avg
-390.50%
5Y Avg
-1635.66%
Market Cap
$2.28B
Operating Margin
24.03%
TTM Avg
25.35%
3Y Avg
27.79%
5Y Avg
25.07%
Market Cap
$2.43B
Operating Margin
-867.87%
TTM Avg
-840.98%
3Y Avg
-774.76%
5Y Avg
-1234.34%
Market Cap
$2.24B
Operating Margin
-42.22%
TTM Avg
-21.11%
3Y Avg
-21.11%
5Y Avg
-21.11%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | $2.35B | -340.16% | -880.11% | -391.07% | -375.67% |
| UFP Technologies, Inc. (UFPT)vs › | $2.34B | 15.25% | 15.68% | 15.36% | 13.51% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 42.26% | 35.06% | 13.24% | -28.82% |
| Disc Medicine, Inc. (IRON)vs › | $2.37B | 0.00% | 0.00% | 0.00% | 0.00% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.38B | -0.74% | -3.89% | -12.55% | -17.88% |
| Liquidia Corporation (LQDA)vs › | $2.30B | -32.45% | -449.54% | -390.50% | -1635.66% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 24.03% | 25.35% | 27.79% | 25.07% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.43B | -867.87% | -840.98% | -774.76% | -1234.34% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.24B | -42.22% | -21.11% | -21.11% | -21.11% |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.49B | -5.13% | 3.60% | 3.31% | 10.24% |
Gross Margin
77.5%
Operating Margin
-340.2%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-05-31 | -1041.73% |
| 2026-02-28 | -1479.45% |
| 2025-11-30 | -612.03% |
| 2025-08-31 | -1157.65% |
| 2025-05-31 | -109.68% |
| 2025-02-28 | -340.67% |
| 2024-11-30 | -486.73% |
| 2024-08-31 | -433.83% |
| 2024-05-31 | -401.42% |
| 2024-02-29 | -272.65% |
| 2023-11-30 | -299.06% |
| 2023-08-31 | -216.67% |
| 2023-05-31 | -87.25% |
| 2023-02-28 | -338.60% |
| 2022-11-30 | -717.82% |
| 2022-08-31 | -432.93% |
| 2022-05-31 | -399.89% |
| 2022-02-28 | -444.28% |
| 2021-11-30 | -513.16% |
| 2021-08-31 | -282.84% |
| 2021-05-31 | -372.50% |
| 2021-02-28 | -489.36% |
| 2020-11-30 | -299.12% |
| 2020-08-31 | -469.82% |
| 2020-05-31 | -316.36% |
| 2020-02-29 | -438.30% |
| 2019-11-30 | -728.46% |
| 2019-08-31 | -24.69% |
| 2019-05-31 | -33.80% |
| 2019-02-28 | -31.08% |
